Mayo Clinic Develops a Lab Test for Inflammatory Demyelinating Diseases

The spectrum ofinflammatory demyelinating diseases (IDD) includes neuromyelitis optica, acute disseminated encephalomyelitis, optic neuritis, and transverse myelitis, all of which need to be differentiated from multiple sclerosis (MS).Mayo Clinic scientists have developed a test for an antibody to myelin oligodendrocyte glycoprotein (MOG) which can help to differentiate the former set of diseases from the latter disease (see:Mayo Clinic develops neuro test that distinguishes demyelinating diseases from MS). Below is an excerpt from the article announcing its availability:Mayo Clinic has launched a first-in-the-U.S. clinical test that will help patients who recently have been diagnosed with an inflammatory demyelinating disease (IDD) but may be unsure of the exact disorder. Neurologic-related diseases commonly affect the brain, optic nerves and the spinal cord, and this new test can distinguish other IDDs such as neuromyelitis optica, acute disseminated encephalomyelitis, optic neuritis, and transverse myelitis from multiple sclerosis (MS).The test uses live cells to identify patients who are positive for an antibody to myelin oligodendrocyte glycoprotein (or “MOG,” for short)....[A Mayo spokesperson said the following:]"we have learned that if patients test positive for MOG antibodies, it generally indicates that it ’s not classical MS,”....“And, more important, some MS treatments have been reported to worsen the disease of patients diag...
Source: Lab Soft News - Category: Laboratory Medicine Authors: Tags: Clinical Lab Industry News Clinical Lab Testing Medical Research Source Type: blogs